Showing results (121-130 of 137) with videos related to

Sort By:
Pageof 14
Drugs & Aging|May 18, 2013
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective studyRoberto Latagliata, Dario Ferrero, Alessandra Iurlo, et al.
Leukemia Research|July 23, 2014
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survivalMassimo Breccia, Luigiana Luciano, Roberto Latagliata, et al.
Annals of Hematology|January 3, 2021
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinibGiovanni Caocci, Olga Mulas, Isabella Capodanno, et al.
Blood|January 9, 2024
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosisIlaria Crespiatico, Mattia Zaghi, Cristina Mastini, et al.
Annals of Hematology|June 1, 2020
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitorsOlga Mulas, Giovanni Caocci, Fabio Stagno, et al.
Cancer|June 24, 2023
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CMLMario Tiribelli, Roberto Latagliata, Massimo Breccia, et al.
Leukemia|March 28, 2026
Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomesLaura Li Gagnon, Andrea Duminuco, Fabio Stagno, et al.
Haematologica|March 2, 2019
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practiceCarmen Fava, Giovanna Rege-Cambrin, Irene Dogliotti, et al.
Annals of Hematology|August 9, 2019
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontlineMonica Crugnola, Fausto Castagnetti, Massimo Breccia, et al.
Blood Cancer Discovery|September 25, 2020
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating FunctionsGiovannino Silvestri, Rossana Trotta, Lorenzo Stramucci, et al.
Pageof 14